GLAUKOS CORP

Glaukos insider buying signals confidence in its glaucoma therapy growth – investors should weigh the bullish momentum against the company’s current earnings outlook.

Glaukos CFO’s fresh 20,000‑share buy signals bullish confidence amid new regulatory wins for NCX 470 in China and Japan, hinting at near‑term upside.

Glaukos CFO’s balanced buy‑sell trade shows confidence in the company’s rising valuation and hedges short‑term volatility while backing its glaucoma therapy future.

GLAUKOS CFO’s mixed buy‑sell trade shows bullish confidence in the glaucoma therapy stock, hinting at future upside despite its negative P/E.

Explore the implications of Navratil Tomas’s recent Glaukos insider sale—understand the impact on liquidity, investor sentiment, and the company’s growth outlook.

Glaukos insider buys signal board confidence amid price dip and a $6 B cap‑growth focus on micro‑injectable glaucoma tech—investors see a potential rebound.

Insider buying at Glaukos Corp signals CEO confidence in new glaucoma therapies – learn how the 2026 Form 4 filings could boost future upside.

Insider sales at Glaukos Corp show routine portfolio rebalancing; executives keep significant stakes while stock remains volatile with a steep negative P/E.

Insider sell‑off at Glaukos Corp. shows a small, routine liquidity move by CDO Navratil Tomas, not a red flag for investors—focus on FDA milestones and pipeline growth.

Glaukos insider Gilliam Joseph’s dual‑side trade signals confidence in the company’s glaucoma therapy pipeline, balancing gains with long‑term equity buildup.